General anti-infectives for systemic use and vaccines | Tenderlake

General anti-infectives for systemic use and vaccines

Contract Value:
-
Notice Type:
Contract Notice
Published Date:
11 July 2023
Closing Date:
04 September 2023
Location(s):
BE332 Arr. Liège (BE Belgium/BELGIQUE-BELGIË)
Description:
Anti-infective drugs

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years (structured market in 31 lots).

The specifications can be obtained in .pdf and .doc format and .xls on request to the Public Procurement Service addressed to

marches.info@chuliege.be with the words: "DDE CSCH - CHULG/23.206".

In case of possible discrepancy between the .pdf model and the other models, this is the first document

(model .pdf) which is authentic.

Clindamycin 300 mg (oral)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Ciprofloxacin 500 mg (oral)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Posaconazole 100 mg (oral)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Voriconazole 200 mg (oral)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Acyclovir 800 mg (oral permission)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Clarithromycin 500 mg (oral) (prolonged/modified release)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Amoxicillin 500 mg (oral) (dispersible tablet)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Flucloxacillin 1 g (injectable form)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Amoxicillin 1 g + Ac. Clavulanic 200 mg and Amoxicillin 2 g + Ac. Clavulanic 200 mg (injectable form)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Piperacilline 4 g + Tazobactam 500 mg (forme injectable)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Cefazolin 1 g and 2 g (form for injection)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Fluconazole 200 mg (oral)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Cefuroxime 750 mg and 1.5 g (form for injection)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Ceftazidime 1 g and 2 g (injectable form)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Meropenem 1 g (injectable form)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Clindamycin 600 mg/ 4ml (injectable form)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Linezolid 600 mg/300 ml (form for injection)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Vancomycin 500 mg and 1000 mg (injectable form)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Moxifloxacin 400 mg/250 ml (form for injection)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Ciprofloxacin 400 mg/200 ml (injectable form)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Caspofungin 50 mg + 70 mg (injectable form)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Voriconazole 200 mg (forme injectable)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Amoxicillin 875 mg + Ac. Clavulanic 125 mg (orally)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Foscarnet 6 g/250 ml (forme injectable)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Fluconazole 200 mg/100 ml (forme injectable)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Cefuroxime 500 mg (oral permission)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Minocycline 100 mg (oral)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Azithromycin 500 mg (oral)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Sulfamethoxazole 800 mg + trimethoprim 160 mg (oral)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Linezolid 600 mg (oral)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Moxifloxacin 400 mg (oral)

The purpose of this contract is the conclusion of a framework agreement for the supply of anti-infective medicinal products for a period of 2 years renewable 1 time for a period of two years

Download full details as .pdf
The Buyer:
Centre Hospitalier Universitaire de Liège
CPV Code(s):
33651000 - General anti-infectives for systemic use and vaccines
33690000 - Various medicinal products